Recent years have witnessed a global shift toward the utilization of real-world data (RWD) and registry-based research to generate evidence that complements traditional randomized controlled trials. National and international regulatory agencies—including the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA)—are actively promoting the regulatory-grade use of observational data under the framework of real-world evidence (RWE).

This paradigm shift reflects several converging trends. First, the limitations of randomized controlled trials (RCTs) in capturing real-world effectiveness, safety in diverse populations, and long-term outcomes have become increasingly apparent. RCTs are often conducted in highly selected populations under controlled conditions, limiting generalizability to routine clinical practice. Second, the proliferation of electronic health records (EHRs), administrative claims databases, disease registries, and patient- generated health data has created unprecedented opportunities to study treatment effects, disease progression, and healthcare utilization in real-world settings. Third, advances in data linkage, privacy-preserving technologies, and distributed research networks have enabled large-scale observational studies that were previously infeasible.

Concurrently, the rapid evolution of big data and artificial intelligence (AI) technologies has expanded the analytical scope from conventional parametric approaches to more flexible, structure-oriented methodologies. Machine learning algorithms can identify complex patterns in high-dimensional data, but their "black box" nature poses challenges for regulatory acceptance and clinical interpretability. There is a growing recognition that rigorous statistical frameworks are needed to bridge the gap between data science innovation and regulatory-grade evidence generation.

In this context, the integration of Distribution Structure Analysis (DSA)—which systematically quantifies distributional heterogeneity and ensures goodness-of-fit—and Directed Acyclic Graphs (DAG)—which explicitly model causal dependencies and confounding structures—represents a timely methodological innovation for the era of data-driven clinical and epidemiological research. DSA addresses the challenge of distributional misspecification in heterogeneous real-world populations, while DAG integration ensures that observational analyses appropriately adjust for confounding and avoid collider bias.

The DSA+DAG framework is particularly relevant for registry research, where patient populations are often more heterogeneous than in RCTs, intercurrent events (e.g., treatment switching, loss to follow-up) are common, and causal inference requires careful adjustment for measured confounders. By providing automated audit trails, explicit estimand specification, and systematic goodness-of-fit assessment, the DSA+DAG framework supports the generation of regulatory-grade real-world evidence that meets the transparency and reproducibility standards required by PMDA, FDA, and EMA.

Furthermore, as healthcare systems increasingly adopt value-based care models and precision medicine approaches, the ability to identify distributional heterogeneity (e.g., subpopulations with distinct treatment responses or cost patterns) becomes critical for resource allocation, risk stratification, and targeted interventions. The DSA+DAG framework provides a principled approach to detecting and characterizing such heterogeneity while maintaining causal validity and regulatory compliance (Figure 1).